Tuesday, December 04, 2018 3:23:27 PM
I had a long response and accidentally deleted it. I’m not writing it again, so here is the summary of it...
The opioid tempo is slowing down. The Trump Administration hammered down on the prescription portion of the problem and I bet if you look the stats are either down or downtrending.
BICX is all over the place with their projects. Now VDM and them are gonna have the next cheaper Narcan, just like BICX101 was to Vivitrol?
And sadly, Suboxone and Methadone are more popular than Naltrexone.
If yinz do get the grant I would suggest selling shortly after the spike... BICX is like 4-5 years away from ANY new drug approval.
Good Luck!c
The opioid tempo is slowing down. The Trump Administration hammered down on the prescription portion of the problem and I bet if you look the stats are either down or downtrending.
BICX is all over the place with their projects. Now VDM and them are gonna have the next cheaper Narcan, just like BICX101 was to Vivitrol?
And sadly, Suboxone and Methadone are more popular than Naltrexone.
If yinz do get the grant I would suggest selling shortly after the spike... BICX is like 4-5 years away from ANY new drug approval.
Good Luck!c
Recent BICX News
- Form 8-K - Current report • Edgar (US Regulatory) • 04/02/2026 07:31:02 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/31/2026 07:04:16 PM
- BioCorRx Inc. to Present at the Life Sciences Virtual Investor Forum December 11th • GlobeNewswire Inc. • 12/10/2025 01:35:00 PM
- Life Sciences Virtual Investor Forum Agenda Announced for December 11th • GlobeNewswire Inc. • 12/09/2025 01:35:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:28:02 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 05:59:04 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/01/2025 08:15:38 PM
